Quan Nguyen MD, MSc, and Sunil Srivastava, MD, offer strategies for offices to continue to follow up with their RETISERT® patients to help ensure continued implant success and determine whether reimplantation may be necessary after 2.5 years.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other products/brand names are trademarks of the respective owners.
©Bausch & Lomb Incorporated. All rights reserved. RET.0036.USA.17